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ABSTRACT
Rising opioid use in the United States has now been 
termed an epidemic. Opioid use is associated with 
considerable morbidity, mortality, and cost to the 
healthcare system. Orthopaedic surgeons play a key 
role in the opioid epidemic by prescribing postoperative 
narcotics. Although our understanding of the quantity 
of narcotics to prescribe postoperatively for analgesia 
is progressing, there is still a paucity of data focused 
on routine postoperative pain protocols. The purpose 
of this article is to review the current options for both 
opioid and non-opioid analgesia and put forth a multi-
subspecialty orthopaedic protocol of postoperative 
pain. On the basis of study findings and the individual 
experiences of surgeons within our orthopaedic 
department, our comprehensive pain protocol includes 
the following considerations: use of non-steroidal anti-
inflammatory drugs on an individual basis, limited use 
of benzodiazepines, use of diazepam in only pediatric 
patients undergoing major procedures, lower doses 
of gabapentin after hip and knee arthroplasty, higher 
doses of gabapentin after spine procedures, general 
use of oxycodone owing to its accessibility, use of 
isolated opioids rather than combined forms, and close 
collaboration with anesthesiologists for determining use 
of peripheral nerve block. Our resultant comprehensive 
pain protocol can provide orthopaedic surgeons with a 
framework to build upon, which will benefit greatly from 
future studies that examine narcotic use with specific 
procedures. 
Keywords: Pain, Postoperative, Narcotic, Opioid, 
Protocol
INTRODUCTION
Nociception is the mechanism by which tissue damage 
is communicated from the periphery to the central 
nervous system. The resulting pain has a large variability 
and is defined as the unpleasant experience associated 
with a given stimulus.1 Pain is a common concern in 
most fields of medicine, especially in orthopaedics. In 
fact, treatment algorithms used in orthopaedics are 
often guided by pain. Despite the common occurrence 
of pain, little is understood about the variability and 
postoperative treatment.
The increased availability of opioid medications 
and the effort to adequately treat pain has led to 
the dramatic rise of opioid use in the United States.2 
Accordingly, opioid-related consequences have 
increased. The United States represents about 4.4% of 
the world’s population but consumes 80% of the global 
opioid supply.3,4 The Centers for Disease Control and 
Prevention estimates that 32,445 deaths occurred in 
2016 due to prescription opioids, which is about 89 
deaths per day.5 In comparison, 36,161 deaths occurred 
due to motor vehicle accidents in 2015.6
It is estimated that orthopaedic surgeons prescribe 
about 7% of prescription opioids in the United States.7 
Additionally, orthopaedic surgeons prescribe more 
opioids than most other specialty physicians owing 
to the pain associated with common orthopaedic 
procedures. Furthermore, orthopaedic surgeons often 
prescribe more narcotics than patients use,8 which 
can contribute to potential abuse and the diversion of 
prescription narcotics to other uses and users.
The challenge of prescribing postoperative narcotic 
medication is learning how to manage an amount 
needed for pain control during an unpredictable time. 
The goal is to find a balance in prescribing sufficient 
quantities of narcotics, offsetting postoperative pain, 
and minimizing potential risks of habituation and 
inappropriate use. Finding a sufficient quantity is 
dependent on multiple variables such as the surgical 
procedure, operating time, preoperative opioid 
exposure, use of non-narcotic agents, and patient 
variability in pain perception.9 Although several of 
these variables remain difficult to quantify, the typical 
opioid quantity for a given surgical procedure appears 
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to be more predictable. The aim of this article is to 
review frequently used postoperative pain regimens and 
put forth a comprehensive protocol of postoperative 
pain management that can be applied to common 
orthopaedic procedures. 
IMPLICATIONS OF A STANDARDIZED 
PAIN PROTOCOL
Use of standardized protocols has become common 
in medicine. Although protocols often evolve as the 
studies expand, implementation of routine protocols 
has proven effective in reducing patient morbidity 
and mortality in multiple applications—ranging 
from preoperative timeout10 to acute management 
of unstable pelvic ring injuries.11 Despite emerging 
reports of average amounts of opioids to prescribe 
postoperatively, data are limited regarding the potential 
benefits of prescribing a defined amount. Routine 
protocols of postoperative pain management can 
potentially improve morbidity and mortality and change 
the landscape of the current opioid crisis.12,13 
NON-STEROIDAL ANTI-INFLAMMATORY 
DRUGS 
Since the discovery of acetylsalicylic acid (ie, aspirin) 
in the bark of a willow tree more than 70 years 
ago, non-steroidal anti-inflammatory medications 
(NSAIDs) have been used for analgesia.14 NSAIDs 
inhibit cyclooxygenase 1 (COX-1) and 2 (COX-2) to 
provide antipyretic, analgesic, anti-inflammatory, and 
antithrombotic effets.15 Historically, the use of NSAIDs 
in the management of orthopaedic injuries has been 
controversial because of concerns of bleeding, delayed 
wound healing, and fracture healing complication.15 In 
children, however, NSAIDs have been shown to decrease 
opioid consumption16,17 and are as effective as opioids in 
reducing pain associated with uncomplicated fractures.18 
Both the risks of NSAIDs and the benefits of decreased 
opioid use favor the inclusion of NSAIDs in a multimodal 
postoperative pain regimen.
Various NSAIDs are available, each one with a varying 
duration of action, adverse effect profiles, analgesic 
strength, and cost.19 Regarding orthopaedic surgical 
procedures, no standard has been set on the “perfect” 
NSAID, nor is there evidence that one NSAID regimen 
is more effective for one procedure over another. 
Therefore, the choice of NSAID should be left to the 
discretion of the surgeon and patient, taking into 
consideration the history of gastrointestinal bleed or 
upset, cardiovascular history, renal health, allergies, 
and associated anticoagulants. For this reason, our 
institution’s orthopaedic department has agreed to use 
NSAIDs on a case-by-case basis rather than universally 
for every procedure. 
OTHER NON-OPIOID MEDICATIONS
Acetaminophen, also known as paracetamol, is a 
frequently employed and readily available analgesic 
in the United States.20 Acetaminophen imparts its 
antipyretic and analgesic effects to the central nervous 
system; additionally, it regulates impact on the 
inflammatory response.21 It is available in both oral and 
intravenous forms, with intravenous typically reserved 
for the immediate postoperative period when patients 
may experience limited oral intake. Acetaminophen 
has become a standard in our pain protocol because of 
favorable adverse effect profile.
Gabapentin is a gamma-aminobutyric acid agonist 
that acts primarily on spinal calcium channels, but 
there are likely other pharmacodynamics that are not 
understood.22 It has been well established that the role 
of gabapentin is reducing phantom limb pain after 
amputation23; however, the role of gabapentin as a 
multimodal agent is less clear in other orthopaedic 
procedures, particularly in arthroplasty.24-26 Two 
randomized controlled trials that used gabapentin 
postoperatively found slightly decreased opioid use 
within the 48-hour period in one trial and no benefit 
in the other.25,26 However, a meta-analysis by Han et 
al27 found that gabapentin significantly reduced opioid 
consumption within the first 24 and 48 hours after 
surgery. The use of gabapentin has been shown to 
be more effective in perioperative pain control after 
lumbar spine procedures,28 however these data are 
confounded by considerable preoperative use. As a 
result of these mixed findings, we incorporated lowered 
doses of gabapentin (300 mg every night) into our 
routine postoperative pain protocol for hip and knee 
arthroplasty. For patients recovering from a spine 
procedure, we use a higher dose (ie, 600 mg every 
night) because many of our patients were accustomed 
to this medication preoperatively. 
Benzodiazepines inhibit transmission on the 
postsynaptic γ-aminobutyric acid (known as GABA) 
neurons.29 Additionally, they act centrally on the spinal 
cord and peripherally on muscle tissue to reduce 
muscle spasms. The risk of respiratory depression with 
opioids and benzodiazepines has been thoroughly 
studied,30 and thus our use of this medication is quite 
limited. In our protocol, diazepam is used solely in 
treating children undergoing major procedures. In our 
experience, this medication is typically used instead of 
opioids for this specific population. 
OPIOID MEDICATIONS
In the central nervous system, opioid medications 
provide analgesia through their agonistic actions on the 
Mu receptor; however, our understanding of the various 
Mu receptors continues to evolve.31 Although opioids 
may be effective for postoperative analgesia, their use 
is not without drawbacks. Fletcher and Martinez32 linked 
intraoperative exposure to opioids to hyperalgesia in 
the immediate postoperative period, highlighting the 
potential risks and early development of tolerance. 
The association between duration of opioid use and 
potential for misuse has also been well studied. Brat 
et al12 found that with each refill, an additional week of 
opioid use, the risk of misuse increased by 44%. The 
many adverse effects of prolonged opioid exposure 
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have been well described (eg, nausea, vomiting, 
constipation, and respiratory depression).33 Thus, 
the primary aim of our multimodal pain protocol was 
to provide sufficient postoperative analgesia while 
minimizing opioid use. 
There are many available choices for oral opioid 
analgesia. The options can be broadly categorized 
into isolated versus combined forms, long versus 
short acting, or by route of administration. For the 
purpose of this review, we limited our discussion 
to oral, short acting isolated, and combined forms. 
Isolated forms include hydrocodone, oxycodone, 
morphine, hydromorphone, methadone, among others. 
Potency, duration of action, and half-life are unique 
to each medication. To provide study uniformity 
for the comparison of opioids, the use of milligram 
morphine equivalents has become standard and is 
readily available on the Centers for Disease Control 
and Prevention website34; however, the accuracy of 
conversion remains debatable.35,36 The isolated opioid 
should be chosen by both the patient and provider 
because the adverse effect profile and analgesic effect 
are similar and dependent on dosage.37 Furthermore, 
Basilico et al38 found no difference between the risk 
of prolonged opioid use and prescription opioid type 
after orthopaedic procedures. For the purposes of our 
protocol, oxycodone is the most easily accessible and 
readily available. 
A few combined forms of opioid include oxycodone 
and ibuprofen, oxycodone and acetaminophen, or 
hydrocodone and acetaminophen.39 Many studies 
have found no differences in the analgesic efficacy 
of combined opioid and NSAID forms or opioid and 
acetaminophen forms.40-43 Furthermore, when combining 
opioid and NSAID medications, there is no evidence 
of synergistic analgesic effect.44 Anecdotally, there 
is a potential benefit of minimizing opioid overdose 
in combined forms, which suggests that a patient 
attempting to misuse or overdose oxycodone and 
acetaminophen will reach toxic levels of acetaminophen 
before respiratory depression. However, there is 
no evidence to support this claim and we strongly 
recommend that providers not rely on this method for 
safety when prescribing opioids. Although combined 
opioid forms may offer convenience, calculating safe 
dosages of acetaminophen and NSAIDs to use in 
conjunction can be burdensome and even dangerous 
for patients. Therefore, the use of isolated opioids in our 
protocol allows us to emphasize narcotic use solely as 
needed after maximizing use of non-narcotic agents. 
Additionally, it allows the patient to discontinue opioids 
early in the postoperative period while continuing the 
use of non-narcotics during recovery.
REGIONAL ANESTHESIA
Regional anesthesia refers to the use of peripheral nerve 
blocks for intraoperative and postoperative analgesia. 
Additionally, it can be used in conjunction with general 
anesthesia or monitored anesthesia care for a given 
procedure. The safety of regional anesthesia has been 
well established.45 Furthermore, regional anesthesia has 
been shown to significantly reduce opioid consumption 
in arthroplasty, fracture treatment, and arthroscopy.46-49 
Although the use of peripheral nerve blocks has been 
widely adopted into our practice as orthopaedic 
surgeons, collaboration with anesthesiologists is 
crucial. Peripheral nerve block locations, medications, 
and dosages continue to change. Because of this, we 
defer their use to our anesthesia colleagues rather 
than implement them into a uniform and standardized 
protocol. Although the choice of peripheral nerve block 
may vary between cases, our anesthesia colleagues 
typically provide interscalene blocks for shoulder 
procedures; infraclavicular blocks for elbow, wrist, 
and hand procedures; combined femoral and sciatic 
blocks for arthroscopic knee procedures; popliteal and 
saphenous blocks for foot and ankle procedures; and 
spinal anesthesia for hip and knee arthroplasty. 
CONCLUSION
To address the lack of a standardized pain protocol, 
surgeons of our orthopaedic department synthesized 
their individual protocols, with gaps subsidized by 
agreeable surgeon-specific preferences. In Appendices 
1 through 7, we present the resultant comprehensive 
postoperative pain protocol. The purpose of the 
protocol is to maximize non-narcotic analgesia and 
provide a standard quantity of opioid for various 
orthopaedic procedures. 
Notably, the protocol focuses on common procedures 
and does not address every possible procedure that 
an orthopaedic surgeon could perform. However, 
it can be applied as a framework for less common 
procedures. Within the protocol, some procedures are 
identified as major or minor depending on the severity 
of the treatment and anticipated postoperative pain 
experienced. Furthermore, we expect deviations from 
the protocol in cases of patient allergies, prior opioid 
exposure, and preoperative medications. 
Early results of implementing a standard pain 
protocol are encouraging but limited to single 
subspecialties.13 To our knowledge, this is the first 
review to put forth a multi-subspecialty protocol. 
Studies evaluating the benefits of a multi-subspecialty 
protocol are currently underway, and future work 
dedicated to minimizing narcotic use remain paramount. 
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Appendix 1. Postoperative protocol for managing pain after common foot and ankle procedures 
Drug ORIF for Ankle Injuries Bunion Surgery
Acetaminophen
   Quantity
   Durationa
80 tablets (500 mg)
2 every 8 h 
80 tablets (500 mg)
2 every 8 h
Ibuprofen
   Quantity
   Duration
40 tablets (800 mg)
1 TID as needed
40 tablets (800 mg) 
1 TID as needed
Oxycodoneb
   Quantity
   Duration
30 tablets (5 mg) 
1 every 6 h as needed
20 tablets (5 mg) 
1 every 6 h as needed
TID, three times a day.
aPatients should take this until pain resolves.  
bPatients should take for breakthrough pain.
Appendix 2. Postoperative protocol for managing pain after common hand procedures
Drug Trigger finger 
release
Carpal tunnel 
release
De Quervain’s 
release
ORIF for DR 
fractures
Acetaminophen
   Quantity
   Durationa
80 tablets (500 mg)
2 every 8 h
“
“
“
“
“
“
Ibuprofen
   Quantity
   Duration
40 tablets (800 mg)
1 TID as needed
“
“
“
“
“
“
Oxycodone
   Quantity
   Durationb
5 tablets (5 mg)
1 every 6 h as needed
“
“
“
“
15 tablets (5 mg) 
“
TID, three times a day; “, same information as in the row to the left; ORIF, open reduction and internal fixation; DR, distal radius. 
aPatients should take this until pain resolves.  
bPatients should take for breakthrough pain.
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Appendix 3. Postoperative protocol for managing pain after common pediatric procedures and conditionsa,b
Drug Minor proceduresc Major proceduresd Scoliosis
Liquids
Hycete
   Quantity
   Duration
0.1 mg/kg 
Every 6 h for 5 days
0.1 mg/kg
Every 6 h for 14 days
0.1 mg/kg 
Every 6 h for 14 days
Ibuprofen
   Quantity
   Duration
10 mg/kg
every 6 h for 5 days
10 mg/kg
Every 6 h for 14 days
--
--
Diazepam
   Quantity
   Duration
--
--
5 mg/5 mL (0.1 mg/kg)
Every 6 h for 7 daysf
5 mg/5mL (0.1 mg/kg)
Every 6 h for 7 daysf
Senna
   Quantity
   Duration
8.8 mg/5mL
Oral syrup for 5 days
8.8 mg/5 mL
Oral syrup for 14 days
8.8 mg/5 mL
Oral syrup for 14 days 
Gabapentin
   Quantity
   Duration
--
--
--
--
300 mg
Every evening for 14 days
Miralax
   Quantity
   Duration
--
--
--
--
17 g 
Every day for 7 days (225 g)i
Pills
Ibuprofen
   Quantity
   Duration
10 mg/kg
Every 6 h for 5 days
10 mg/kg
Every 6 h for 14 days
--
--
Tylenol
   Quantity
   Duration
10 mg/kg
Every 4 h for 5 days
10 mg/kg 
Every 4 h for 14 days
10 mg/kg
Every 4 h for 14 days
Oxycodone
   Quantity
   Duration
0.1 mg/kg 
Every 4 h for 5 days
0.1 mg/kg
Every 4 h for 7 daysg
0.1 mg/kg
Every 4 hours for 7 daysg
Diazepam
   Quantity
   Duration
--
--
5 mg/5 mL (0.1 mg/kg)
Every 6 hh
5 mg/5 mL (0.1 mg/kg)
Every 6 hh
Docusate
   Quantity
   Duration
50 mg 
BID for 5 days 
50 mg
BID for 14 days
--
--
Senna
   Quantity
   Duration
--
--
--
--
8.8 mg /5 mL
Oral syrup for 14 days
Gabapentin
   Quantity
   Duration
--
--
--
--
300 mg 
Every evening for 14 days
Miralax
   Quantity
   Duration
--
--
--
--
17 g
Every day for 7 days (255 g)i
--, not applicable; BID, twice a day. 
aFor infants < 1 year: use hycet (7.5 mg hydrocodone / 325 mg paracetamol in 15 mL) 0.1mg/kg every 6 h for 5 days. Solution comes in 
concentration as above, so typically give 2 mL for a 10 kg baby.
bConsider a daily aspirin 325 mg for 28 days for all adolescent females, especially those on birth control.
cExamples of minor procedures are as follows: tendon-Achilles lengthening, surgical fixation of supracondylar fractures, epiphysiodesis, 
tendon transfers, hardware removal, etc.   
dExamples of major procedures are as follows: acetabular and femoral osteotomies, surgical fixation of femur and tibia fractures, calcaneal 
osteotomies, etc. 
eHydrocodone or paracetamol.
fFor muscle spasms.
gDo not exceed 60 tablets. 
hFor muscle spasms; do not exceed 30 tablets.
iTirate to soft stools.
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Appendix 4. Postoperative protocol for managing pain after common spine procedures
Drug Inpatient management plana
Gabapentin
   Quantity
   Duration
600 mg
QHS
Acetaminophen        
   Quantity
   Duration
1000 mg (≤ 4000 mg)
Every 6 h 
Ketorolacb
   Quantity
   Duration
30 mg (≤ 210 mg)
Every 6 h for first 24 h
Ibuprofenb
   Quantity
   Duration
800 mg (≤ 3200 mg)
Every 6 h as needed after first 24 h
Dexamethasonec
   Quantity
   Duration
8 mg
PO daily for 48 h 
Methocarbamol       
   Quantity
   Duration
500 mg (≤ 4000 mg)
QID as needed for muscle spasm
Opioids after inpatient management plan medications are maxed outd
Oxycodone
  Quantity
  Duration
5 mg
Every 4 h as needed for pain
Oxycodone
  Quantity
  Duration
10 mg
Every 4 h as needed for pain
Morphine
  Quantity
  Duration
2-4 mg 
Every 4 h as needed for pain
Dilaudid
  Quantity
  Duration
0.5-2 mg
Every 4 h as needed
Bowel regimen
Senna
  Quantity
  Duration
--
BID
Miralax
  Quantity
  Duration
17 g
Powder BID if no bowel movement by postoperative day 3
Discharge medication (until 2 weeks postoperatively)
Gabapentin
   Quantity
   Duration
600 mg (28 300 mg tablets)
QHS 
Acetaminophen        
   Quantity
   Duration
1000 mg (56 tablets)
Every 6 h (≤ 4000 mg daily)
Meloxicam
   Quantity
   Duration
7.5 mg (14 tablets)
Every day as needed
Oxycodone
   Quantity
   Duration
5 mg (80 tablets) 
Every 4 h as needed 
Senna
   Quantity
   Duration
28 tablets
1 tablet BID while continuing opioid use
Promethazine
  Quantity
  Duration
12.5 mg (30 tablets)
Every 6 h as needed for nausea 
QHS, every night before bed; PO, orally; QID, for times a day; --, not applicable; BID, twice a day. 
aApplied to both elective and trauma patients unless contraindicated. If previous opioid use is greater than 120 morphine equivalents (ie, 80 
mg of oxycodone) per day, defer to consultation with inpatient pain management service.
bBecuase this is a nonsteroidal anti-inflammatory drug, it should be avoided if there is concern for poor bone healing. Give with proton pump 
inhibitors (ie, PPI) or H2 receptor blockers.
cAvoid if concern for poor wound healing.
dFor continuous opioids, avoid basal rates—to be used in low dose for breakthrough pain in the immediate postoperative period.
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Appendix 5. Postoperative protocol for managing pain after total joint arthroplasty
Drug Inpatient management plan
Toradol       
   Quantity
   Duration
15 mg
IV Every 6 h for 48 h (hold for h/o GI bleed or GFR < 60)
Meloxicama
   Quantity
   Duration
7.5 mg 
PO every day for remainder of stay
Tylenol
   Quantity
   Duration
1 g
PO every 8 h (hold for hepatitis C)
Decadron
   Quantity
   Duration
4 mg
IV every day for 2 days (hold for diabetes)
Gabapentin
   Quantity
   Duration
300 mg
PO QHS
Famotidine 
   Quantity
   Duration
20 mg 
BID
For patients aged < 70 years
Oxycontin
   Quantity
   Duration
10 mg 
PO BID (monitor closely in OSA) 
Oxycodone
   Quantity
   Duration
5 mg
PO every 4 h as needed for moderate pain
Oxycodone
   Quantity
   Duration
10 mg 
PO every 4 h as needed for severe pain
Morphine
   Quantity
   Duration
2 mg
IV every 4 h as needed for intractable pain only
For patients aged > 70 years (hold oxycontin)
Oxycodone
   Quantity
   Duration
5 mg
PO every 4 h (monitor closely for AMS and delirium)
Tramadol
   Quantity
   Duration
50 mg
PO every 6 h as needed for moderate pain
Oxycodone
   Quantity
   Duration
5 mg
PO every 4 h as needed for moderate pain
Morphine
   Quantity
   Duration
2 mg
IV every 4 h as needed for intractable pain only
Outpatient management plan
Aspirin        
   Quantity
   Duration
81 mg (30 tablets) 
BID (vs Lovenox) for 30 days
Meloxicam
   Quantity
   Duration
7.5 mg (30 tablets)
PO daily for 30 days
Gabapentin
   Quantity
   Duration
300 mg (30 tablets)
PO QHS for 30 days
Famotidine 
   Quantity
   Duration
20 mg (30 tablets)
PO daily for 30 days
Continued on the next page
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Tylenol
   Quantity
   Duration
1 g
PO TID for 2 weeks, then as needed for up to 6 weeks
Zofran
   Quantity
   Duration
4 mg (10 tablets)
PO every 6 h daily for 2 weeks
Docusate
   Quantity
   Duration
100 mg (28 tablets)
PO BID for 2 weeks
For patients aged < 70 yearsb,c
Oxycodone
   Quantity
   Duration
5 mg (60 tablets)
PO 1-2 tablets every 4-6 h as needed for 2 weeks
Oxycodone
   Quantity
   Duration
5 mg (30 tablets)
PO 1 tablet every 6 h (from 2 to 6 weeks)
GFR, glomerular filtration rate; GI, gastrointestinal; QHS, every night before bed; BID, twice a day; IV, intravenous; PO, orally; OSA, obstructive 
sleep apnea; AMS, altered mental status; TID, twice a day.
aTake after toradol. 
bNo narcotics beyond 6 weeks, switch to tramadol if as-needed medication is still required.
cFor patients aged > 70 years, consider oxycodone if well tolerated while in-house and high pain level, or tramadol (50 mg, 60 tablets) at 1 
tablet orally every 6 h.
Appendix 6. Postoperative protocol for managing pain after trauma-related procedures
Drug Minor proceduresa Major proceduresb
Naprosyn 
   Quantity
   Duration
500 mg
BID 1 tablet every 12 h for 3 days then BID 
(Disp #30 refill 2)c
“
“
Tylenol
   Quantity
   Duration
325 mg
2 tablets every 6 h for 3 days then 1-2 tablets 
every 6 h (Disp #60 refill 2)c
“
“
Oxycodone
   Quantity
   Duration
5 mg 
1 tablet every 6 h (Disp #10)c
“
1 tablet every 6 h (Disp #30)c
Lovenox
   Quantity
   Duration
--
--
40 mg 
Daily for 2 weeks followed by aspirin
Aspirin
   Quantity
   Duration
81 mg 
BID for 4 weeks (Disp #14)
“
“ to follow lovenox
Zofran
   Quantity
   Duration
4 mg
Every 8 h (Disp #5 refill 1)d
“
“
Docusate
   Quantity
   Duration
100 mg 
Daily for 14 days (Disp #14 refill 1)
“
“
Gabapentin
   Quantity
   Duration
--
--
300 mg
Every evening for 14 days for amputations
“, same information as in the row to the left; BID, twice a day; Disp, dispense; --, not applicable. 
aMinor procedures include debridement, surgical treatment of flexor tenosynovitis, surgical fixation of finger fractures, etc. 
bMajor procedures include surgical fixation of ankle, tibial plateau, acetabular, patella, both bone, and distal radius fractures as well as 
amputations, etc.
cAs needed for pain. 
dAs needed for nausea.
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Appendix 7. Postoperative protocol for managing pain after sports medicine proceduresa
Drug Minor proceduresb Major proceduresc Hip scope Shoulder arthroplasty
Naprosyn 
   Quantity
   Duration
500 mg
1 tablet every 12 h for 3 
days then BIDd (Disp #30 
refill 2)
“
“
“
1 tablet every 12 h for 
30 days (Disp #60 
refill 2)
“
1 tablet every 12 h for 
3 days then BIDd (Disp 
#30 refill 2)
Tylenol
   Quantity
   Duration
325 mg
2 tablets every 6 h for 3 
days then 1-2 tablets every 
6 hd (Disp #60 refill 2)
“
“
“
“
“
“
Oxycodone
   Quantity
   Duration
5 mg
1 tablet every 6 hd (Disp 
#30)
5 mg
1 tablet every 6 hd 
(Disp #10)
“
1 tablet every 6 hd 
(Disp #30)
“
“
Aspirin
   Quantity
   Duration
81 mg
BID for 2 weeks (Disp #28)
“
“
325 mg 
QD for 4 weeks (Disp 
#5 refill 1)
“
OD for 4 weeks (Disp 
#28)
Zofran
   Quantity
   Duration
4 mg 
Every 8 he (Disp #5 refill 1)
“
“
“
“
“ 
“
“, same information as in the row to the left; BID, twice a day; Disp, dispense; --, not applicable; QD, once a day. 
aPlease use this for all patients undergoing treatment with sports medicine attendings unless directed otherwise by the attending, or if a 
contraindication is identified for an individual patient.
bMinor procedures include debridement, non-implant procedures, minimal to no bone work, and implant removal.
cMajor procedures include those that require use of implants. 
dAs needed for pain. 
eAs needed for nausea.
